Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients

BACKGROUND: Dexamethasone (DXM) is commonly used in the management of cerebral edema in patients diagnosed with glioblastoma multiforme (GBM). Bevacizumab (BEV) is FDA-approved for the progression or recurrence of GBM but has not been shown to improve survival when given for newly diagnosed patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Shields, Lisa B. E., Shelton, Brent J., Shearer, Andrew J., Chen, Li, Sun, David A., Parsons, Sarah, Bourne, T. David, LaRocca, Renato, Spalding, Aaron C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628380/
https://www.ncbi.nlm.nih.gov/pubmed/26520780
http://dx.doi.org/10.1186/s13014-015-0527-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628380/
https://www.ncbi.nlm.nih.gov/pubmed/26520780
http://dx.doi.org/10.1186/s13014-015-0527-0

Ejemplares similares